{"ModuleTitle": "Company Description", "CompanyName": "TG Therapeutics, Inc.", "Symbol": "TGTX", "Address": "2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, New York, 10014, United States of America", "Phone": "(212) 554-4484", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company dedicated to developing and delivering\r\nmedicines for patients with B-cell mediated diseases, including Chronic\r\nLymphocytic Leukemia (CLL), non-Hodgkin Lymphoma (NHL) and Multiple Sclerosis\r\n(MS). We have developed a robust B-cell directed research and development (R&D)\r\nplatform for identification of key B-cell pathways of interest and rapid\r\nclinical testing. Currently, we have five B-cell targeted drug candidates in\r\nclinical development, with the lead two therapies, ublituximab (TG-1101) and\r\numbralisib (TGR-1202), in pivotal trials for CLL, NHL and MS. Ublituximab is a\r\nnovel anti-CD20 monoclonal antibody (mAb) that has been glycoengineered for\r\nenhanced potency over first generation antibodies. Umbralisib is an oral, once\r\ndaily, dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a\r\ndifferentiated safety profile. When used together in combination therapy,\r\nublituximab and umbralisib are referred to as \"U2\".&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001558370-20-001897.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Michael Sean Weiss", "title": "Executive Chairman, President & CEO"}, {"name": "Sean A. Power", "title": "Chief Financial Officer, Secretary & Treasurer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}